Cite
A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.
MLA
Zhang, Haiping, et al. “A Novel Virtual Screening Procedure Identifies Pralatrexate as Inhibitor of SARS-CoV-2 RdRp and It Reduces Viral Replication in Vitro.” PLoS Computational Biology, vol. 16, no. 12, Dec. 2020, pp. 1–20. EBSCOhost, https://doi.org/10.1371/journal.pcbi.1008489.
APA
Zhang, H., Yang, Y., Li, J., Wang, M., Saravanan, K. M., Wei, J., Tze-Yang Ng, J., Tofazzal Hossain, M., Liu, M., Zhang, H., Ren, X., Pan, Y., Peng, Y., Shi, Y., Wan, X., Liu, Y., & Wei, Y. (2020). A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro. PLoS Computational Biology, 16(12), 1–20. https://doi.org/10.1371/journal.pcbi.1008489
Chicago
Zhang, Haiping, Yang Yang, Junxin Li, Min Wang, Konda Mani Saravanan, Jinli Wei, Justin Tze-Yang Ng, et al. 2020. “A Novel Virtual Screening Procedure Identifies Pralatrexate as Inhibitor of SARS-CoV-2 RdRp and It Reduces Viral Replication in Vitro.” PLoS Computational Biology 16 (12): 1–20. doi:10.1371/journal.pcbi.1008489.